Repligen (NASDAQ:RGEN) Trading Up 4.2%

Repligen Co. (NASDAQ:RGEN) shares were up 4.2% during mid-day trading on Monday . The stock traded as high as $155.39 and last traded at $153.70. Approximately 150,524 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 653,618 shares. The stock had previously closed at $147.55.

Analyst Upgrades and Downgrades

RGEN has been the topic of a number of analyst reports. Guggenheim initiated coverage on shares of Repligen in a research note on Tuesday, June 18th. They issued a “neutral” rating on the stock. Stephens reiterated an “overweight” rating and set a $170.00 price target on shares of Repligen in a report on Tuesday, July 30th. UBS Group decreased their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. JPMorgan Chase & Co. upped their price objective on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. Finally, Deutsche Bank Aktiengesellschaft raised Repligen from a “hold” rating to a “buy” rating and reduced their target price for the stock from $180.00 to $155.00 in a report on Wednesday, June 26th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Repligen presently has an average rating of “Moderate Buy” and a consensus price target of $189.57.

Repligen Stock Performance

The business has a 50-day moving average of $137.60 and a 200 day moving average of $163.68. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The company has a market cap of $8.40 billion, a PE ratio of 601.04, a PEG ratio of 5.72 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The firm had revenue of $154.07 million during the quarter, compared to analyst estimates of $154.11 million. During the same quarter in the prior year, the firm earned $0.53 EPS. The business’s revenue for the quarter was down 3.2% compared to the same quarter last year. Equities research analysts anticipate that Repligen Co. will post 1.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Anthony Hunt bought 2,000 shares of the firm’s stock in a transaction on Friday, June 14th. The shares were bought at an average price of $124.08 per share, for a total transaction of $248,160.00. Following the purchase, the chief executive officer now owns 165,177 shares in the company, valued at $20,495,162.16. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, VP Ralf Kuriyel sold 4,465 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the transaction, the vice president now directly owns 19,261 shares in the company, valued at $3,190,969.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Anthony Hunt bought 2,000 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The shares were acquired at an average price of $124.08 per share, with a total value of $248,160.00. Following the transaction, the chief executive officer now directly owns 165,177 shares of the company’s stock, valued at approximately $20,495,162.16. The disclosure for this purchase can be found here. Company insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

A number of institutional investors have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC boosted its holdings in shares of Repligen by 18,449.1% during the 4th quarter. International Assets Investment Management LLC now owns 58,615 shares of the biotechnology company’s stock valued at $10,539,000 after purchasing an additional 58,299 shares during the last quarter. Cerity Partners LLC grew its holdings in Repligen by 69.1% during the 4th quarter. Cerity Partners LLC now owns 2,668 shares of the biotechnology company’s stock valued at $480,000 after buying an additional 1,090 shares in the last quarter. Daiwa Securities Group Inc. increased its stake in Repligen by 3.1% in the 4th quarter. Daiwa Securities Group Inc. now owns 3,300 shares of the biotechnology company’s stock worth $593,000 after acquiring an additional 100 shares during the last quarter. abrdn plc raised its holdings in shares of Repligen by 1.4% during the 4th quarter. abrdn plc now owns 5,192 shares of the biotechnology company’s stock worth $934,000 after acquiring an additional 71 shares in the last quarter. Finally, Verdence Capital Advisors LLC boosted its position in shares of Repligen by 36.7% during the 4th quarter. Verdence Capital Advisors LLC now owns 2,956 shares of the biotechnology company’s stock valued at $531,000 after acquiring an additional 793 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.